R

CNH Industrial: Periodic Report on $1 Billion Buyback Program

Retrieved on: 
星期五, 十一月 17, 2023

CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company.

Key Points: 
  • CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company.
  • Across a history spanning over two centuries, CNH Industrial has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success.
  • As a truly global company, CNH Industrial’s 40,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.
  • For more information and the latest financial and sustainability reports visit: cnhindustrial.com
    For news from CNH Industrial and its Brands visit: media.cnhindustrial.com

Jeremy Caldwell, Ph.D., Accomplished Biopharma Executive, Company Creator and R&D Leader, Joins Red Tree Venture Capital as Partner

Retrieved on: 
星期四, 十一月 16, 2023

SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Red Tree Venture Capital (“Red Tree”), a West Coast-centric, early stage-biased life science venture capital firm, today announced that Jeremy Caldwell, Ph.D., a widely respected biopharmaceutical executive and research and development leader, whose accomplishments span from the creation of innovative drug development companies to driving the discovery, development and translation of novel therapies, has joined the firm as a partner. Dr. Caldwell brings Red Tree a range of deep industry expertise built throughout a career involving roles as a member of both industry and the venture community. In alignment with the firm’s West Coast focus, he has forged deep ties within the San Diego and San Francisco Bay Area biotechnology communities.

Key Points: 
  • Dr. Caldwell brings Red Tree a range of deep industry expertise built throughout a career involving roles as a member of both industry and the venture community.
  • Based in San Diego, Dr. Caldwell’s addition to Red Tree illustrates the firm’s increased emphasis on targeting company creation and investment opportunities emanating from the greater San Diego area.
  • “Jeremy has led an accomplished career in the biopharmaceutical space, achieving impressive successes from the perspectives of executive, R&D leader, and company builder.
  • He currently serves as a member of the board of Red Tree portfolio companies Sardona Therapeutics and Biograph 55.

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 十一月 16, 2023

BERKELEY, Calif. and MAINZ, Germany, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its financial results of the third quarter ending September 30, 2023 and provided a corporate update.

Key Points: 
  • ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023
    BERKELEY, Calif. and MAINZ, Germany, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its financial results of the third quarter ending September 30, 2023 and provided a corporate update.
  • “This past quarter was an important period of progress for the Company highlighted by ColoFuture’s spectacular readout of results.
  • During the quarter, Mainz Biomed established a strategic partnership with Ärztliches Labor Dr. Buhlmann, a respected player in PCR-based analysis.
  • Throughout the third quarter, Mainz Biomed continued to prepare for commencing patient enrollment in the ReconAAsense clinical trial (ClinicalTrials.gov Identifier: NCT05636085).

CNH brands dominate at Farm Machine 2024 awards

Retrieved on: 
星期三, 十一月 15, 2023

CNH is proud to announce that we have taken home the most medals at the Farm Machine 2024 awards.

Key Points: 
  • CNH is proud to announce that we have taken home the most medals at the Farm Machine 2024 awards.
  • The awards, formerly known as Machine of the Year, celebrate the best Ag inventions of the season.
  • “I want to thank our team for representing CNH and our brands so well.
  • For more information and the latest financial and sustainability reports visit: cnhindustrial.com
    For news from CNH Industrial and its Brands visit: media.cnhindustrial.com

NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
星期二, 十一月 14, 2023

SANTA ANA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (NKGen or the Company), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, today announced its financial results for the third quarter ended September 30, 2023, and provided business highlights.

Key Points: 
  • 90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer’s disease composite score (ADCOMS) following 11 weeks.
  • Research and development (R&D) expenses: R&D expenses for the third quarter of 2023 were $3.9 million compared to $4.1 million in the same period in 2022.
  • General and administrative (G&A) expenses: G&A expenses for the third quarter of 2023 were $3.0 million compared to $1.9 million in the same period in 2022.
  • The increase was primarily due to stock option grants made during the first quarter of 2023.

SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
星期二, 十一月 14, 2023

DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Key Points: 
  • DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.
  • “Recent clinical and regulatory successes have significantly improved and strengthened our company’s prospects,” said Eric Schlorff, SeaStar Medical CEO.
  • SeaStar Medical expects regulatory approval for the SCD-ADULT in the first half of 2025 and commercial launch in the second half of 2025.
  • The Company issued two convertible notes each for $0.5 million in August 2023 and a third convertible note for $0.5 million in September 2023.

Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期二, 十一月 14, 2023

SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • In August 2023, Icosavax provided an update from its Phase 1b extension trial of IVX-121 against RSV in older adults.
  • Prior to Icosavax, Antu held roles of increasing responsibility at GreenLight Biosciences, International Aids Vaccines Initiative (IAVI), Novartis Vaccines & Diagnostics, and GSK Vaccines.
  • Research and development expenses include non-cash stock-based compensation expenses of $2.7 million for the three months ended September 30, 2023.
  • General and administrative expenses include non-cash stock-based compensation expenses of $3.9 million for the three months ended September 30, 2023.

Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
星期二, 十一月 14, 2023

LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • We also remain very active within the the medical community with a booth at Kidney Week and positive results published on the phosphate binding capacity for OLC,” concluded Dr. Gupta.
  • Unicycive believes that results from this pivotal trial will enhance the OLC data package from preclinical studies and our previously disclosed bioequivalence study.
  • Dr. Kenkare-Mitra brings Unicycive expertise spanning research, preclinical and clinical development, translational medicine, manufacturing, and regulatory.

KULR Technology Group Reports Third Quarter 2023 Financial Results; Company on Track with Analysts’ Q4 Forecasts

Retrieved on: 
星期二, 十一月 14, 2023

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a global leader in sustainable energy management, today reported results for the third quarter ended September 30, 2023.

Key Points: 
  • SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a global leader in sustainable energy management, today reported results for the third quarter ended September 30, 2023.
  • Cash and Accounts Receivable: As of September 30, 2023, the Company had cash and accounts receivable combined of $2.46 million.
  • Gross Margins: Gross margin was 44% in the quarter ending September 30, 2023, compared to 33% in the same period last year.
  • Selling, General and Administrative (SG&A) Expenses: SG&A expenses increased to $4.79 million in the third quarter of 2023 from $4.35 million in the same period last year.

Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results

Retrieved on: 
星期二, 十一月 14, 2023

VANCOUVER, Wash. and NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2023.

Key Points: 
  • Research and development expenses were $11.0 million for the third quarter of 2023 compared to $15.5 million for the corresponding prior year period.
  • Net loss was $22.0 million for the third quarter of 2023, as compared to $27.3 million for the corresponding prior year period.
  • Cash, cash equivalents, and short-term investments as of September 30, 2023 was $113.5 million, compared to $124.6 million as of June 30, 2023.
  • Absci continues to anticipate at least ten new Active Programs in 2023, based on the company's current partnership pipeline.